Evidence map›Paper›PMID 36131937›Full record

ArticleFrontiers in immunology2022

Autoantibodies elicited with SARS-CoV-2 infection are linked to alterations in double negative B cells.

Moriah J Castleman, Megan M Stumpf, Nicholas R Therrien, Mia J Smith, Kelsey E Lesteberg, Brent E Palmer, James P Maloney, William J Janssen, Kara J Mould, J David Beckham and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. B cells in non-lymphoid tissues.Nature reviews. Immunology · 2025
    Review
  6. Article
  7. The role of fatty acid metabolism on B cells and B cell-related autoimmune diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Moriah J CastlemanDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Megan M StumpfDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Nicholas R TherrienDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Mia J SmithDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Kelsey E LestebergDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Brent E PalmerDepartment of Medicine, Division of Allergy and Clinical Immunology, University of Colorado School of Medicine, Aurora, CO, United States.
James P MaloneyDepartment of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
William J JanssenDepartment of Medicine, National Jewish Health, Denver, CO, United States.
Kara J MouldDepartment of Medicine, National Jewish Health, Denver, CO, United States.
J David BeckhamDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Roberta PelandaDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Raul M TorresDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
University of Colorado Denver · USNational Jewish Health · USUniversity of Colorado Anschutz Medical Campus · US

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Lung Macrophage Programming in Acute Lung InjuryR35HL140039 · NHLBI · NATIONAL JEWISH HEALTH · PI JANSSEN, WILLIAM · 2018 to 2024
$6.4M
Humoral Immunity by Anergic B cellsR01AI136534 · NIAID · UNIVERSITY OF COLORADO DENVER · PI TORRES, RAUL MARTIN · 2018 to 2022
$2.6M
Studies of human B cell tolerance, from a humanized mouse model to human beingsR01AI124474 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2016 to 2020
$2.3M
Development of a vaccination platform for emerging flavivirus infectionsR01AI153724 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI John David Beckham · 2022 to 2026
$2.3M
Role and mechanisms of the PI3K pathway in B cell toleranceR01AI152535 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2020 to 2024
$2.1M
Metabolic Reprogramming of Recruited Alveolar Macrophages by Arginine In Acute Lung InjuryK08HL141648 · NHLBI · NATIONAL JEWISH HEALTH · PI MOULD, KARA J · 2018 to 2022
$798k
Testing an alternative model of central B cell toleranceR21AI131639 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2017 to 2018
$428k
Contribution of c-Maf to regulatory B cells and antibody-secreting cellsR21AI156232 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2021 to 2022
$428k
NCATS NIH HHS UL1 TR002535NHLBI NIH HHS K08 HL141648NHLBI NIH HHS R35 HL140039NIAID NIH HHS R01 AI124474NIAID NIH HHS R01 AI136534NIAID NIH HHS R01 AI152535NIAID NIH HHS R01 AI153724NIAID NIH HHS R21 AI131639NIAID NIH HHS R21 AI156232
6 · The paper itself

Abstract

Double negative (DN) B cells (CD27-IgD-) comprise a heterogenous population of DN1, DN2, and the recently described DN3 and DN4 subsets. In autoimmune disease, DN2 cells are reported to be precursors to autoreactive antibody secreting cells and expansion of DN2 cells is linked to elevated interferon levels. Severe SARS-CoV-2 infection is characterized by elevated systemic levels of pro-inflammatory cytokines and serum autoantibodies and expansion of the DN2 subset in severe SARS-CoV-2 infection has been reported. However, the activation status, functional capacity and contribution to virally-induced autoantibody production by DN subsets is not established. Here, we validate the finding that severe SARS-CoV-2 infection is associated with a reduction in the frequency of DN1 cells coinciding with an increase in the frequency of DN2 and DN3 cells. We further demonstrate that with severe viral infection DN subsets are at a heightened level of activation, display changes in immunoglobulin class isotype frequency and have functional BCR signaling. Increases in overall systemic inflammation (CRP), as well as specific pro-inflammatory cytokines (TNFα, IL-6, IFNγ, IL-1β), significantly correlate with the skewing of DN1, DN2 and DN3 subsets during severe SARS-CoV-2 infection. Importantly, the reduction in DN1 cell frequency and expansion of the DN3 population during severe infection significantly correlates with increased levels of serum autoantibodies. Thus, systemic inflammation during SARS-CoV-2 infection drives changes in Double Negative subset frequency, likely impacting their contribution to generation of autoreactive antibodies.

Indexed as

COVID-19Tumor Necrosis Factor-alphaAutoantibodiesB-LymphocytesHumansImmunoglobulin DImmunoglobulin IsotypesInflammationInterferonsInterleukin-6SARS-CoV-2AutoantibodiesImmunoglobulin DImmunoglobulin IsotypesInterferonsInterleukin-6Tumor Necrosis Factor-alphaautoreactiveB cellsDN1DN2DN3double negativeinflammationSARS–CoV–2

Identifiers

PMID36131937
PMCPMC9484582
OpenAlexW4294605666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.